FORM 2
THE PATENTS ACT, 1970
(39 of 1970)
&
The Patent Rules, 2003
COMPLETE SPECIFICATION
(See section 10 and rule 13)
STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND
MANUFACTURING PROCESS THEREOF
SUN PHARMACEUTICAL INDUSTRIES LIMITED
A company incorporated under the Laws of India having their corporate office at SUN HOUSE,
201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400063, Maharashtra, India.
The following specification particularly describes the nature of this invention and the manner
in which it is to be performed:
2
CROSS REFERENCE
The present patent application is a national phase of PCT/IB2021/059176 which claims
the benefit of the priority date of Indian Provisional Patent Application No. 202121037917
filed on August 20, 2021.
5 FIELD OF THE INVENTION
The present invention relates to a stable nanomicellar ophthalmic solution comprising
cyclosporine and a method of preparing the nanomicellar solution. The present invention
further relates to the stable nanomicellar solution comprising cyclosporine form with
characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous
10 cyclosporine. The present invention also relates to use of this stable nanomicellar
ophthalmic solution in dry eye.
BACKGROUND OF THE INVENTION
Cyclosporine nanomicellar ophthalmic solutions are generally disclosed in U.S. Patent No.
10,918,694, wherein the ophthalmic solution comprises comprising 0.087-0.093 wt %
15 cyclosporine, a polyoxyl lipid or fatty acid and a polyalkoxylated alcohol. Preferably, it
comprises 0.087-0.093 wt % cyclosporine, 0.5-5% of one or more selected from the group
consisting of HCO-40, HCO-60, HCO-80 and HCO-100; and about 0.01-0.1% octoxynol-
40. Further, it discloses methods of preparing such cyclosporine solutions. The method
includes dissolution of cyclosporine in polyoxyl castor oil such as hydrogenated castor oil
20 and a polyalkoxylated alcohol such as octoxynol at 60°C prior to addition in an aqueous
phase. Specifically, the preparation method of ophthalmic solution consists of the
following steps: HCO-40 is melted in a flask heated to about 60°C with stirring. When
liquefied, the required amount of cyclosporine is added and mixed until dissolved and
uniform. Then, octoxynol-40 is heated to about 60°C and when liquefied, is added to the
25 cyclosporine HCO-40 mixture. Water for injection at about 25°C is charged into the flask
containing the dissolved cyclosporine and stirred until dissolved. Other excipients are then
added, such as sodium chloride and phosphate buffer and then PVP-K90 and mixed until
dissolved and brought to the final volume with water for injection. However, current
methods have a problem in that when cyclosporine is dissolved in the polyoxyl castor oil,
30 such as HCO-40, due to the difference in solubility and stability of different forms of
cyclosporine, there may be a difference in stability of different batches during
3
manufacturing. The result is that some batches are not stable and the cyclosporine
precipitates out of solution.
Further, cyclosporine in different forms shows different solubility and stability.
Cyclosporine with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 is the
most soluble form of cyclosporine and is useful in 5 the preparation of solution
formulations, however this is not the most stable form and it may convert to the less
soluble forms of cyclosporine, thus affecting the stability of the solution. This form may
convert to a more stable and less soluble cyclosporine with characteristic XRD peaks at 2-
theta (deg.) 7.4, 8.7, 14.4 and 17.5 during dissolution of cyclosporine in surfactants at 55-
10 60°C. Similarly, it may change to another less soluble form of cyclosporine with
characteristic XRD peaks at 2-theta (deg.) 8.5, 9.3, 11.6 and 20.3. Further, the amorphous
form, which is also one of the more soluble forms and useful in the preparation of solution
formulations, may also recrystallize to these two less soluble forms. Such a conversion is
facilitated by several factors not limited to moisture, water, solvent temperature and so on.
15 This conversion also depends on stresses like temperature, long storage at higher
temperature, and the like. The process needs modification depending on the form of
cyclosporine used, such that the amorphous form and the form with characteristic XRD
peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 needs wetting followed by complete
dissolution at the temperature up to 70°C. However, if the less soluble forms are used,
20 temperatures as high as 130°C are needed. Further, during the manufacturing steps, due to
the instability and conversions, the solution is to be manufactured with tight control of
API specification, process temperature and time to avoid interconversion of forms. It is
rather, difficult to identify to what extent this conversion has taken place before
completing the manufacturing process to get the nanomicellar cyclosporine. This leads to a
25 formation of seeds within the composition either at the initial stage of the process or
during storage at higher temperatures, which later crystallized out from the drug product
rendering the product unuseful. The soft mesophasic or liquid crystalline form of
cyclosporine formed as intermediate in the non-aqueous phase may be responsible for
such instability.
30 Thus, there is a need for a stable formulation and method of its preparation to prevent
conversion to less soluble forms of cyclosporine during the manufacturing process and
during storage. The present invention discloses a stable nanomicellar ophthalmic
formulation and an improved method of making such stable formulation. The method for
4
making the formulation results in a stable formulation irrespective of any form of
cyclosporin being used in the formulation. The method does not lead to conversion of one
form to another. More specifically, does not lead to conversion of the soluble form of
cyclosporine to the less soluble forms of cyclosporine and further prevents precipitation of
cyclosporine in the formulation on l 5 ong-term stability.
SUMMARY OF THE INVENTION
One of the objectives of the present invention, according to some embodiments, a method
of making a stable nanomicellar ophthalmic formulation comprising:
cyclosporine, a polyoxyl lipid or fatty acid, and a polyalkoxylated alcohol, wherein the
10 ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior to the
complete dissolution of the cyclosporine, adding octoxynol-40; and
15 c) mixing the resulting mixture with the aqueous vehicle.
The present inventors have surprisingly found that the solution stability of cyclosporine A
at 35°C-40oC was higher than that of 55°C-60oC and thus, reducing the temperature to
35°C-40oC overcomes the above mentioned stability concerns of the formulation and
provides for a more stable formulation.
20 In another aspect, the present invention is drawn to a stable nanomicellar ophthalmic
formulation comprising:
cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
25 temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior to the
complete dissolution of the cyclosporine, adding octoxynol-40; and
c) mixing the resulting mixture with the aqueous vehicle.
5
In one aspect, mixing the aqueous vehicle at a temperature of at 35°C±2°C. In another
aspect, mixing the aqueous vehicle at a temperature of 55±2°C.
In one aspect, the present invention provides a stable nanomicellar ophthalmic formulation
comprising cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4
5 and 15.9.
In another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation comprising an amorphous form of cyclosporine.
In another aspect, a method of making a stable nanomicellar ophthalmic formulation
comprising: cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an
10 aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) keeping mixture A under vacuum to remove foam;
15 c) optionally, lowering the temperature of mixture A to a temperature of 35°C±2°C
prior to the complete dissolution of the cyclosporine;
d) adding octoxynol-40; and
e) mixing the resulting mixture with the aqueous vehicle.
In another embodiment, it provides a stable nanomicellar ophthalmic formulation
20 comprising:
cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
25 b) keeping mixture A under vacuum to remove foam;
c) optionally, lowering the temperature of mixture A to a temperature of 35°C±2°C
prior to the complete dissolution of the cyclosporine;
d) adding octoxynol-40; and
e) mixing the resulting mixture with the aqueous vehicle.
6
It was surprisingly found that the on keeping the mixture under vacuum, the bubbles are
dragged up and accumulate on the surface from where bubbles were gradually removed
and the bottom portion is cleared up. So dissolution under vacuum or removal of foams
intermittently during dissolution leads to faster dissolution and may not require the
lowering of the temperature of the mixture. Thus, 5 overcomes the above mentioned
stability concerns of the formulation and provides for a more stable formulation.
In one aspect, mixing the aqueous vehicle at a temperature of at 35°C±2°C. In another
aspect, mixing the aqueous vehicle at a temperature of 55±2°C.
In one aspect, the present invention provides a stable nanomicellar ophthalmic formulation
10 comprising cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4
and 15.9.
In another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation comprising an amorphous form of cyclosporine.
In yet another aspect, the present invention provides a stable nanomicellar ophthalmic
15 formulation comprising:
cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 127-130°C until completely dissolved to form a mixture A;
20 b) adding octoxynol-40 to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of at 127-
130°C,
wherein, cyclosporine is present in a form having characteristic XRD peaks at 2-theta
(deg.) 7.4, 8.7, 14.4 and 17.5.
25 In yet another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation comprising:
cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
7
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 127-130°C until completely dissolved to form a mixture A;
b) adding octoxynol-40 to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of 127-
5 130°C,
wherein, cyclosporine is present in a form with characteristic XRD peaks at 2-theta (deg.)
8.5, 9.3, 11.6 and 20.3.
In a preferred aspect, the present invention provides a method of making a stable
nanomicellar ophthalmic formulation comprising:
10 0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40, and
an aqueous vehicle,
wherein the method comprising the steps of:
15 a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior to the
complete dissolution of the cyclosporine, adding octoxynol-40; and
c) mixing the resulting mixture with the aqueous vehicle.
20 In one aspect, the aqueous vehicle is mixed at a temperature of at 35°C±2°C. In another
aspect, the aqueous vehicle is mixed at a temperature of 55±2°C.
In a preferred aspect, the present invention also provides a stable nanomicellar ophthalmic
formulation prepared by a method as described above.
In a preferred aspect, the present invention provides a method of making a stable
25 nanomicellar ophthalmic formulation comprising:
0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40, and
8
an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) keeping mixture 5 A under vacuum to remove foam;
c) optionally, lowering the temperature of mixture A to a temperature of 35°C±2°C
prior to the complete dissolution of the cyclosporine;
d) adding octoxynol-40; and
e) mixing the resulting mixture with the aqueous vehicle.
10 In one aspect, the aqueous vehicle is mixed at a temperature of at 35°C±2°C. In another
aspect, the aqueous vehicle is mixed at a temperature of 55±2°C.
In a preferred aspect, the present invention also provides a stable nanomicellar ophthalmic
formulation prepared by a method as described above.
In one aspect, the stable nanomicellar ophthalmic formulation further comprises:
15 about 0.20-0.550 wt % sodium phosphate monobasic,
about 0.23-0.465 wt % sodium phosphate dibasic,
about 0.05 wt % sodium chloride,
about 0.3 wt % povidone,
sodium hydroxide/hydrochloric acid to adjust the pH, and
20 water for injection.
In one aspect, the present invention provides a stable nanomicellar ophthalmic
formulation, wherein the pH of the formulation is about 5.0 to 8.0. More preferably, the
pH of the formulation is about 6.5 to 7.2.
Further, the present invention provides a stable nanomicellar ophthalmic formulation
25 wherein the osmolality of the formulation is between about 150 to about 200 mOsmol/kg.
In another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation comprising cyclosporine form with characteristic XRD peaks at 2-theta (deg.)
6.9, 7.8, 9.4 and 15.9.
9
In yet another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation comprising an amorphous form of cyclosporine.
In another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation, wherein the formulation is substantially free of a cyclosporine form with
characteristic XRD peaks 5 at 2-theta (deg.) 7.4, 8.7, 14.4 and 17.5.
In another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation, wherein the formulation is substantially free of a cyclosporine form with
characteristic XRD peaks at 2-theta (deg.) 8.5, 9.3, 11.6 and 20.3.
In another aspect, the present invention provides a stable nanomicellar ophthalmic
10 formulation, prepared by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior to the
complete dissolution of the cyclosporine, adding octoxynol-40; and
15 c) then mixing the resulting mixture with an aqueous vehicle at 35°C±2°C, wherein
the mixture A is lowered to a temperature of 35°C±2°C in less than 65 minutes.
Preferably, the mixture A is lowered to a temperature of 35°C±2°C in 40-50 minutes.
In one aspect, mixing the mixture A of step (a) for 20-30 minutes. Preferably, 20-25
minutes, more preferably, mixing the mixture A of step (a) for 20 ±2 minutes.
20 In one aspect, lowering the temperature of to 35°C±2°C and stirring for 60-70 minutes.
Preferably, stirring the mixture for 60±5 minutes at a temperature of 35°C±2°C.
In yet another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation comprising:
0.09 wt % cyclosporine,
25 about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40, and
an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
10
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 127-130°C until completely dissolved to form a mixture A;
b) adding octoxynol-40 to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of at 127-
5 130°C,
wherein, cyclosporine is present in a form having characteristic XRD peaks at 2-theta
(deg.) 7.4, 8.7, 14.4 and 17.5.
In yet another aspect, drawn to a stable nanomicellar ophthalmic formulation comprising:
0.09 wt % cyclosporine,
10 about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40, and
an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
15 temperature of 127-130°C until completely dissolved to form a mixture A;
b) adding octoxynol-40 to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of 127-
130°C,
wherein, cyclosporine is present in a form with characteristic XRD peaks at 2-theta (deg.)
20 8.5, 9.3, 11.6 and 20.3.
In yet another aspect, the present invention provides a method of making a stable
nanomicellar ophthalmic formulation comprising:
0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
25 about 0.05 wt % octoxynol-40,
about 0.20-0.550 wt % sodium phosphate monobasic,
about 0.23-0.465 wt % sodium phosphate dibasic,
about 0.05 wt % sodium chloride,
11
about 0.3 wt % povidone,
sodium hydroxide/hydrochloric acid to adjust the pH, and
water for injection,
wherein the method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl 5 castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior to the
complete dissolution of the cyclosporine, adding octoxynol-40 to form an API
mixture;
10 c) adding API mixture to Water for Injection (WFI);
d) adding remaining excipients to step (c) in the order of sodium phosphate
monobasic, then sodium phosphate dibasic, then sodium chloride, and then
polyvinylpyrrolidone;
e) adjusting the pH to 6.5 to 7.2 and bringing to the final volume with WFI.
15 In one aspect, mixing the mixture A of step (a) for 20-30 minutes. Preferably, 20-25
minutes, more preferably, mixing the mixture A of step (a) for 20 ±2 minutes.
In one aspect, lowering the temperature of the mixture A to 35°C±2°C in less than 65
minutes. Preferably, lowering the temperature of the mixture A to 35°C±2°C in 40-50
minutes.
20 In another aspect, stirring the mixture of step (b) for 60-70 minutes. Preferably, stirring the
mixture for 60±5 minutes at a temperature of 35°C±2°C.
In one aspect, mixing the API mixture to WFI at a temperature of 35°C±2°C. In another
aspect, mixing the API mixture to WFI at a temperature of 55±2°C.
In yet another aspect, the present invention provides a method of making a stable
25 nanomicellar ophthalmic formulation comprising:
0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40,
about 0.20-0.550 wt % sodium phosphate monobasic,
12
about 0.23-0.465 wt % sodium phosphate dibasic,
about 0.05 wt % sodium chloride,
about 0.3 wt % povidone,
sodium hydroxide/hydrochloric acid to adjust the pH, and
5 water for injection,
wherein the method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) keeping mixture A under vacuum to remove foam;
10 c) optionally, lowering the temperature of mixture A to a temperature of 35°C±2°C
prior to the complete dissolution of the cyclosporine;
d) adding octoxynol-40;
e) adding API mixture to Water for Injection (WFI);
f) adding remaining excipients to step (c) in the order of sodium phosphate
15 monobasic, then sodium phosphate dibasic, then sodium chloride, and then
polyvinylpyrrolidone; and
g) adjusting the pH to 6.5 to 7.2 and bringing to the final volume with WFI.
In one aspect, mixing the mixture A of step (a) for 20-30 minutes. Preferably, 20-25
minutes, more preferably, mixing the mixture A of step (a) for 20 ±2 minutes.
20 In one aspect, lowering the temperature of the mixture A to 35°C±2°C in less than 65
minutes. Preferably, lowering the temperature of the mixture A to 35°C±2°C in 40-50
minutes.
In one aspect, mixing the API mixture to WFI at a temperature of 35°C±2°C. In another
aspect, mixing the API mixture to WFI at a temperature of 55±2°C.
25 In a more preferred aspect, the present invention provides for a stable nanomicellar
ophthalmic formulation prepared by any of the method as described above.
BRIEF DESCRIPTION OF THE DRAWINGS
13
Figure 1(a) and Figure 1(b) depict cyclosporine nanomicellar ophthalmic formulations
prepared by methods described in Example 1(a) and Example 1(b), respectively. Figure
1(a) discloses that no particles were observed, while Figure 1(b) discloses that particles
were observed on stability.
Figure 2 depicts characteristic X-ray powder diffraction (XRPD) 5 patterns of cyclosporine
with a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and
15.9 (A), a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 7.4, 8.7,
14.4 and 17.5 (B), a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 8.5,
9.3, 11.6 and 20.3 (C), and an amorphous form of cyclosporine.
10 Figures 3(a) to 3(d) depict the solubility behavior of different cyclosporine forms at 55oC.
Figure 3(a) depicts the solubility behavior of CsA form with characteristic XRD peaks at
2-theta (deg.) 6.9, 7.8, 9.4 and 15.9. Figure 3(b) depicts solubility behavior of a CsA form
with characteristic XRD peaks at 2-theta (deg.) 7.4, 8.7, 14.4 and 17.5. Figure 3(c) depicts
solubility behaviour of a CsA form with characteristic XRD peaks at 2-theta (deg.) 8.5,
15 9.3, 11.6 and 20.3, and Figure 3(d) depicts solubility behaviour of amorphous CsA.
Figure 4 depicts X-ray powder diffraction (XRPD) patterns of a precipitated cyclosporine
from solution prepared when cyclosporine is dissolved in Kolliphore RH 40 at higher
exposure and temperature.
Figure 5 depicts X-ray powder diffraction (XRPD) patterns of a precipitated cyclosporine
20 when cyclosporine is dissolved in Kolliphore RH 40 kept it for a longer time till the
precipitation occurred.
DETAILED DESCRIPTION OF THE INVENTION
One embodiment of the present disclosure is a stable nanomicellar ophthalmic
formulation. The ophthalmic formulation comprises cyclosporine, a polyoxyl lipid or
25 fatty acid, and a polyalkoxylated alcohol.
Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising:
cyclosporine, a polyoxyl lipid or fatty acid, and a polyalkoxylated alcohol, wherein the
ophthalmic formulation is made by a method comprising the steps of:
30 a) mixing the cyclosporine with the polyoxyl lipid or fatty acid at a temperature of
55°C or above to form a mixture A; and
14
b) lowering the temperature of mixture A to a temperature not higher than 40°C prior
to the complete dissolution of the cyclosporine.
Preferably, mixing the cyclosporine with the polyoxyl lipid or fatty acid is done at a
temperature of 55°C-60°C to form a mixture A. Preferably, mixture A is lowered to a
temperature of 35oC- 40°C prior to the complete dissolution 5 of the cyclosporine. More
preferably, mixing the cyclosporine with the polyoxyl lipid or fatty acid is done at a
temperature of 55°C±2°C to form a mixture A; and mixture A is lowered to a temperature
not higher than 35°C±2°C prior to the complete dissolution of the cyclosporine. Further,
the method comprises adding the polyalkoxylated alcohol and then mixing the resulting
10 mixture with an aqueous vehicle at 35°C±2°C. In another aspect, the resulting mixture
with an aqueous vehicle at a temperature of 55±2°C.
Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising:
cyclosporine, a polyoxyl lipid or fatty acid, and a polyalkoxylated alcohol, and an aqueous
15 vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the polyoxyl lipid or fatty acid at a temperature of
55°C±2°C or above to form a mixture A;
b) keeping mixture A under vacuum to remove foam;
20 c) optionally, lowering the temperature of mixture A to a temperature of 35°C±2°C
prior to the complete dissolution of the cyclosporine, adding polyalkoxylated alcohol;
and
d) mixing the resulting mixture with the aqueous vehicle.
In one aspect, the aqueous vehicle is mixed at a temperature of at 35°C±2°C. In another
25 aspect, the aqueous vehicle is mixed at a temperature of 55±2°C.
It was found that during the dissolution of hydrophobic molecule like cyclosporine A
(CsA) in polyoxyl lipid such as polyoxyl hydrogenated castor oil, it was found that air was
entrapped in the bulk in a form of bubbles and creates foam. This happens irrespective of
temperature during the drug dissolution process, either 55°C or even when the temperature
30 was reduced to 35°C. This may delay the wetting and dissolution of cyclosporine as this
entrapped air may make a boundary between cyclosporine particles and water. It was
15
surprisingly found that the on keeping the mixture under vacuum, the bubbles are dragged
up and accumulate on the surface from where bubbles were gradually removed and the
bottom portion is cleared up. So dissolution under vacuum or removal of foams
intermittently during dissolution leads to faster dissolution and may not require the
lowering 5 of the temperature of the mixture.
In one aspect, the method of making a stable nanomicellar ophthalmic formulation
comprises cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4
and 15.9.
In another aspect, the method of making a stable nanomicellar ophthalmic formulation
10 comprises an amorphous form of cyclosporine.
Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising cyclosporine, a polyoxyl lipid or fatty
acid, a polyalkoxylated alcohol, and an aqueous vehicle, wherein the ophthalmic
formulation is made by a method comprising the steps of:
15 a) mixing the cyclosporine with a polyoxyl lipid or fatty acid at a temperature of 127-
130°C until completely dissolved to form a mixture A;
b) adding the polyalkoxylated alcohol to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of at 127-
130°C,
20 wherein the cyclosporine is present in a form having characteristic XRD peaks at 2-theta
(deg.) 7.4, 8.7, 14.4 and 17.5.
In yet another aspect, the cyclosporine is present in a form with characteristic XRD peaks
at 2-theta (deg.) 8.5, 9.3, 11.6 and 20.3.
Another embodiment of the present disclosure is a stable nanomicellar ophthalmic
25 formulation comprising cyclosporine, a polyoxyl lipid or fatty acid, and a polyalkoxylated
alcohol, wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the polyoxyl lipid or fatty acid at a temperature of
55°C or above to form a mixture A; and
b) lowering the temperature of mixture A to a temperature not higher than 40°C prior
30 to the complete dissolution of the cyclosporine.
16
Preferably, mixing the cyclosporine with the polyoxyl lipid or fatty acid is done at a
temperature of 55°C-60°C to form a mixture A. Preferably, mixture A is lowered to a
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with the polyoxyl lipid is done at a temperature of
55°C±2°C to form a mixture A; and mixture A is lowered to a temperature 5 not higher than
35°C±2°C prior to the complete dissolution of the cyclosporine. Further, the method
comprises adding polyalkoxylated alcohol and then mixing the resulting mixture with an
aqueous vehicle at 35°C±2°C. In another aspect, the resulting mixture is mixed with the
aqueous vehicle at a temperature of 55±2°C.
10 In one aspect, the present invention provides a stable nanomicellar ophthalmic formulation
comprising cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4
and 15.9.
In another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation comprising an amorphous form of cyclosporine.
15 In another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation comprising: cyclosporine, a polyoxyl lipid or fatty acid, and a polyalkoxylated
alcohol, and an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the polyoxyl lipid or fatty acid at a temperature of
20 55°C±2°C or above to form a mixture A;
b) keeping mixture A under vacuum to remove foam;
c) optionally, lowering the temperature of mixture A to a temperature of 35°C±2°C
prior to the complete dissolution of the cyclosporine, adding polyalkoxylated alcohol;
and
25 d) mixing the resulting mixture with the aqueous vehicle.
In one aspect, the aqueous vehicle is mixed at a temperature of at 35°C±2°C. In another
aspect, the aqueous vehicle is mixed at a temperature of 55±2°C.
In one aspect, the stable nanomicellar ophthalmic formulation comprises cyclosporine
form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9.
30 In another aspect, the stable nanomicellar ophthalmic formulation comprises an
amorphous form of cyclosporine.
17
In yet another aspect, the present invention provides a stable nanomicellar ophthalmic
formulation comprising:
cyclosporine, a polyoxyl lipid or fatty acid, a polyalkoxylated alcohol, and an aqueous
vehicle wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with a polyoxyl lipid or fatty acid 5 at a temperature
of 127-130°C until completely dissolved to form a mixture A;
b) adding the polyalkoxylated alcohol to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of at
127-130°C,
10 wherein the cyclosporine is present in a form having characteristic XRD peaks at 2-theta
(deg.) 7.4, 8.7, 14.4 and 17.5.
In yet another aspect, the cyclosporine is present in a form with characteristic XRD peaks
at 2-theta (deg.) 8.5, 9.3, 11.6 and 20.3.
Another embodiment of the present disclosure is a method of making a stable
15 nanomicellar ophthalmic formulation comprising a cyclosporine, a polyoxyl lipid or fatty
acid, and a polyalkoxylated alcohol, wherein the ophthalmic formulation is made by a
method comprising the steps of: mixing the cyclosporine with the polyoxyl lipid or fatty
acid at a temperature of 55°C or above to form a mixture A; and preventing the formation
of the cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 7.4, 8.7, 14.4 and
20 17.5 (B in Figure 2) by altering the temperature of mixture A prior to the complete
dissolution of the cyclosporine.
Preferably, mixing the cyclosporine with the polyoxyl lipid or fatty acid is done at a
temperature of 55°C-60°C to form a mixture A. Preferably, mixture A is lowered to a
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
25 preferably, mixing the cyclosporine with the polyoxyl lipid is done at a temperature of
55°C±2°C to form a mixture A; and mixture A is lowered to a temperature not higher than
35°C±2°C prior to the complete dissolution of the cyclosporine. In one aspect, the method
of making a stable nanomicellar ophthalmic formulation comprises cyclosporine with
characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 (A in Figure 2). In another
30 aspect, the method of making a stable nanomicellar ophthalmic formulation comprises an
amorphous form of cyclosporine. Further, the method comprises adding the
18
polyalkoxylated alcohol and then mixing the resulting mixture with an aqueous vehicle at
35°C±2°C. In another aspect, the resulting mixture is mixed with the aqueous vehicle at a
temperature of 55±2°C.
Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising a cyclosporine, a 5 polyoxyl lipid or fatty
acid, and a polyalkoxylated alcohol, wherein the ophthalmic formulation is made by a
method comprising the steps of: mixing the cyclosporine with the polyoxyl lipid or fatty
acid at a temperature of 55°C or above to form a mixture A; and applying vacuum to the
mixture to prevent the formation of the cyclosporine form with characteristic XRD peaks
10 at 2-theta (deg.) 7.4, 8.7, 14.4 and 17.5 (B in Figure 2).
Preferably, mixing the cyclosporine with the polyoxyl lipid or fatty acid is done at a
temperature of 55°C-60°C to form a mixture A. Optionally, the mixture A is lowered to a
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with the polyoxyl lipid is done at a temperature of
15 55°C±2°C to form a mixture A; optionally lowering to a temperature not higher than
35°C±2°C prior to the complete dissolution of the cyclosporine. Further, the method
comprises adding the polyalkoxylated alcohol and then mixing the resulting mixture with
an aqueous vehicle at 35°C±2°C. In another aspect, the resulting mixture is mixed with the
aqueous vehicle at a temperature of 55±2°C.
20 Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising a cyclosporine, a polyoxyl lipid or fatty
acid, and a polyalkoxylated alcohol, wherein the ophthalmic formulation is made by a
method comprising the steps of: mixing the cyclosporine with the polyoxyl lipid or fatty
acid at a temperature of 55°C or above to form a mixture A; and preventing the formation
25 of the cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 8.5, 9.3, 11.6 and
20.3 (C in Figure 2) by altering the temperature of mixture A prior to the complete
dissolution of the cyclosporine.
Preferably, mixing the cyclosporine with the polyoxyl lipid or fatty acid is done at a
temperature of 55°C-60°C to form a mixture A. Further, mixture A is lowered to a
30 temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with the polyoxyl lipid is done at a temperature of
55°C±2°C to form a mixture A; and mixture A is then lowered to a temperature not higher
19
than 35°C±2°C prior to the complete dissolution of the cyclosporine. In one aspect, the
method of making a stable nanomicellar ophthalmic formulation comprises cyclosporine
with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 (A in Figure 2). In
another aspect, the method of making a stable nanomicellar ophthalmic formulation
comprises an amorphous form of cyclosporine. Further, the method 5 comprises adding the
polyalkoxylated alcohol and then mixing the resulting mixture with an aqueous vehicle at
35°C±2°C. In another aspect, the resulting mixture is mixed with the aqueous vehicle at a
temperature of 55±2°C.
Another embodiment of the present disclosure is a method of making a stable
10 nanomicellar ophthalmic formulation comprising a cyclosporine, a polyoxyl lipid or fatty
acid, and a polyalkoxylated alcohol, wherein the ophthalmic formulation is made by a
method comprising the steps of: mixing the cyclosporine with the polyoxyl lipid or fatty
acid at a temperature of 55°C or above to form a mixture A; and applying vacuum to the
mixture to prevent the formation of the cyclosporine form with characteristic XRD peaks
15 at 2-theta (deg.) 8.5, 9.3, 11.6 and 20.3 (C in Figure 2).
Preferably, mixing the cyclosporine with the polyoxyl lipid or fatty acid is done at a
temperature of 55°C-60°C to form a mixture A. Optionally, the mixture A is lowered to a
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with the polyoxyl lipid is done at a temperature of
20 55°C±2°C to form a mixture A; optionally lowering to a temperature not higher than
35°C±2°C prior to the complete dissolution of the cyclosporine. Further, the method
comprises adding the polyalkoxylated alcohol and then mixing the resulting mixture with
an aqueous vehicle at 35°C±2°C. In another aspect, the resulting mixture is mixed with the
aqueous vehicle at a temperature of 55±2°C.
25 Another embodiment of the present disclosure is a stable nanomicellar ophthalmic
formulation comprising cyclosporine, a polyoxyl lipid or fatty acid, and a polyalkoxylated
alcohol, wherein the formulation is a solution; and the formulation exhibits stability at
room temperature (20-25oC) for 6 to at least 24 months. Typically, the ophthalmic
formulations are stable when maintained at room temperature for at least 6 months, at least
30 8 months, at least 10 months, at least 12 months, at least 14 months, at least 16 months, at
least 18 months, at least 20 months and at least 24 months.
20
In another embodiment, the present disclosure provides a stable nanomicellar ophthalmic
formulation that exhibits stability at 2oC to 8oC for 6 to at least 24 months. Typically, the
ophthalmic formulations are stable when maintained at 2oC to 8oC for at least 6 months, at
least 8 months, at least 10 months, at least 12 months, at least 14 months, at least 16
months, at least 18 months, at least 5 20 months and at least 24 months.
Another embodiment of the present disclosure is a method of treating or preventing an
ocular disease or condition, the method comprising administering the formulation of any
of the preceding embodiments after 6 to at least 24 months of the manufacture of the
formulation to a patient in need thereof.
10 In another embodiment, the present disclosure is a stable nanomicellar ophthalmic
formulation of any of the preceding embodiments, for use in the treatment of an ocular
disease or condition. Preferably, the ocular disease or condition is dry eye syndrome.
Materials useful in the formulations of the present disclosure include, but are not limited
to, those disclosed in U.S. Patent No. 10,918,694.
15 As they are used here, the terms “cyclosporin”, “cyclosporine”, “cyclosporine A”, or
“CsA” may be used interchangeably and includes pharmaceutically acceptable salts of the
same.
As used herein in connection with numerical values, the terms "approximately" and
"about" mean +/-10% of the indicated value, including the indicated value.
20 As used herein, the term “substantially free” refers to an amount of 10% or less of the
indicated substance, such as another form, preferably 8%, 5%, 4%, 3%, 2%, 1%, 0.5%, or
less of another form.
As used herein, the term “polyoxyl lipid or fatty acid” refers to mono- and diesters of
lipids or fatty acids and polyoxyethylene diols. Polyoxyl lipids or fatty acids may be
25 numbered (“n”) according to the average polymer length of the oxyethylene units (e.g., 40,
60, 80, 100) as is well understood in the art. The term “n≥40 polyoxyl lipid” means that
the polyoxyl lipid or fatty acid has an average oxyethylene polymer length equal to or
greater than 40 units. Stearate hydrogenated castor oil and castor oil are common
lipids/fatty acids commercially available as polyoxyl lipids or fatty acid, however, it is
30 understood that any lipid or fatty acid could polyoxylated to become a polyoxyl lipid or
fatty acid as contemplated herein. Examples of polyoxyl lipid or fatty acids include
21
without limitation hydrogenated polyoxyl castor oil such as HCO-40, HCO-60, HCO-80,
HCO-100, or polyoxyl 40 stearate, polyoxyl 35 castor oil.
As used herein, the term "micelle" or "nanomicelle" refers to an aggregate (or cluster) of
surfactant molecules. Micelles only form when the concentration of surfactant is greater
than the critical micelle concentration (CMC). Surfactants are 5 chemicals that are
amphipathic, which means that they contain both hydrophobic and hydrophilic groups.
Micelles can exist in different shapes, including spherical, cylindrical, and discoidal. A
micelle comprising at least two different molecular species is a mixed micelle. The in
some embodiments, ophthalmic compositions of the present disclosure include an
10 aqueous, clear, mixed micellar solution.
In some embodiments the formulations include, but are not limited to, nanomicelles, as
disclosed in U.S. Patent No. 10,918,694. For example, ophthalmic compositions can be
administered topically to the eye as biocompatible, aqueous, clear mixed micellar
solutions. The compositions have the drugs incorporated and/or encapsulated in micelles
15 which are dispersed in an aqueous medium.
In some aspects of embodiments, the polyoxyl lipid or fatty acid is a polyoxyl castor oil.
In some embodiments, the polyoxyl lipid or fatty acid is one or more selected from
hydrogenated polyoxyl castor oil such as HCO-40, HCO-60, HCO-80 or HCO-100. In
some embodiments the polyoxyl lipid or fatty acid (such as a polyoxyl castor oil such as
20 HCO-60, HCO-80 or HCO-100) is present between 0.5 and 2%, or 0.7 and 2%, or 1 and
6%; or 2 and 6%; or 2 and 6%; or 3 and 6%; or 4 and 6%; or 2 and 5%; or 3 and 5%; or 3
and 5%; or 2 and 6%; or about 4%; or greater than 0.7%; or greater than 1%, or greater
than 1.5%; or greater than 2%; or greater than 3%; or greater than 4% by weight of the
formulation. In some embodiments, the polyoxyl lipid is HCO-40. In some aspects of
25 embodiments, the polyoxyl lipid is HCO-60. In some embodiments, the polyoxyl lipid is
HCO-80. In some embodiments, the polyoxyl lipid is HCO-100.
In some aspects of embodiments, the formulation includes a polyalkoxylated alcohol. In
some embodiments, the polyalkoxylated alcohol is octoxynol-40. In some aspects of
embodiments, the formulation includes a polyalkoxylated alcohol (such as octoxynol-40)
30 present between 0.002 and 4%; or between 0.005 and 3%; or between 0.005 and 2%; or
between 0.005 and 1%; or between 0.005 and 0.5%; or between 0.005 and 0.1%; or
between 0.005 and 0.05%; or between 0.008 and 0.02%; or between 0.01 and 0.1%; or
22
between 0.02 and 0.08%; or between 0.005 and 0.08%; or about 0.05%, or about 0.01% by
weight of the formulation.
One embodiment of the present disclosure is a stable nanomicellar ophthalmic
formulation. The ophthalmic formulation comprises cyclosporine, a hydrogenated
polyoxyl castor oil, and octoxynol-40. Preferably, the hydrogenated 5 polyoxyl castor oil is
hydrogenated 40 polyoxyl castor oil (HCO-40). Preferably, the ophthalmic formulation
comprises 0.09 wt % of cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil,
and 0.05 wt % of octoxynol-40.
Another embodiment of the present disclosure is a method of making a stable
10 nanomicellar ophthalmic formulation comprising cyclosporine, a hydrogenated polyoxyl
castor oil, and octoxynol-40, wherein the ophthalmic formulation is made by a method
comprising the steps of:
a) mixing the cyclosporine with a hydrogenated polyoxyl castor oil at a temperature
of 55°C or above to form a mixture A; and
15 b) lowering the temperature of mixture A to a temperature not higher than 40°C prior
to the complete dissolution of the cyclosporine.
Preferably, mixing the cyclosporine with a hydrogenated polyoxyl castor oil is done at a
temperature of 55°C-60°C to form a mixture A. Preferably, mixture A is lowered to a
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
20 preferably, mixing the cyclosporine with the hydrogenated polyoxyl castor oil is done at a
temperature of 55°C±2°C to form a mixture A; and mixture A is then lowered to a
temperature not higher than 35°C±2°C prior to the complete dissolution of the
cyclosporine. Further, the method comprises adding octoxynol-40 and then mixing the
resulting mixture with an aqueous vehicle at 35°C±2°C. In another aspect, the aqueous
25 vehicle is mixed at a temperature of 55±2°C.
Preferably, the hydrogenated polyoxyl castor oil is hydrogenated 40 polyoxyl
castor oil (HCO-40). More preferably, the ophthalmic formulation comprises 0.09 wt % of
cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt % of
octoxynol-40.
30 Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising cyclosporine, a hydrogenated polyoxyl
23
castor oil, and octoxynol-40, wherein the ophthalmic formulation is made by a method
comprising the steps of:
a) mixing the cyclosporine with a hydrogenated polyoxyl castor oil at a temperature
of 55°C or above to form a mixture A; and
b) keeping mixture 5 A under vacuum to remove foam;
c) optionally, lowering the temperature of mixture A to a temperature of 35°C±2°C
prior to the complete dissolution of the cyclosporine, adding octoxynol-40; and
d) mixing the resulting mixture with the aqueous vehicle.
Preferably, mixing the cyclosporine with a hydrogenated polyoxyl castor oil is done at a
10 temperature of 55°C-60°C to form a mixture A. Optionally, mixture A is lowered to a
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with the hydrogenated polyoxyl castor oil is done at a
temperature of 55°C±2°C to form a mixture A; and optionally lowering the temperature to
not higher than 35°C±2°C prior to the complete dissolution of the cyclosporine. Further,
15 the method comprises adding octoxynol-40 and then mixing the resulting mixture with an
aqueous vehicle at 35°C±2°C. In another aspect, the aqueous vehicle is mixed at a
temperature of 55±2°C.
Preferably, the hydrogenated polyoxyl castor oil is hydrogenated 40 polyoxyl castor oil
(HCO-40). More preferably, the ophthalmic formulation comprises 0.09 wt % of
20 cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt % of
octoxynol-40.
Another embodiment of the present disclosure is a stable nanomicellar ophthalmic
formulation comprising cyclosporine, a hydrogenated polyoxyl castor oil, and octoxynol-
40, wherein the ophthalmic formulation is made by a method comprising the steps of:
25 a) mixing the cyclosporine with the hydrogenated polyoxyl castor oil at a temperature
of 55°C or above to form a mixture A; and
b) lowering the temperature of mixture A to a temperature not higher than 40°C prior
to the complete dissolution of the cyclosporine.
Preferably, mixing the cyclosporine with a hydrogenated polyoxyl castor oil is done at a
30 temperature of 55°C-60°C to form a mixture A. Preferably, mixture A is lowered to a
24
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with the hydrogenated polyoxyl castor oil is done at a
temperature of 55°C±2°C to form a mixture A; and then mixture A is lowered to a
temperature not higher than 35°C±2°C prior to the complete dissolution of the
cyclosporine. Further, the method comprises adding octoxynol-5 40 and then mixing the
resulting mixture with an aqueous vehicle at 35°C±2°C. In another aspect, the aqueous
vehicle is mixed at a temperature of 55±2°C.
Preferably, the hydrogenated polyoxyl castor oil is hydrogenated 40 polyoxyl castor oil
(HCO-40). More preferably, the ophthalmic formulation comprises 0.09 wt % of
10 cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt % of
octoxynol-40.
Another embodiment of the present disclosure relates to a method of making a stable
nanomicellar ophthalmic formulation comprising:
cyclosporine, a polyoxyl lipid or fatty acid, and a polyalkoxylated alcohol, wherein the
15 ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior to the
complete dissolution of the cyclosporine;
20 c) adding octoxynol-40; and
d) mixing the resulting mixture with the aqueous vehicle.
Another embodiment of the present disclosure is a stable nanomicellar ophthalmic
formulation comprising cyclosporine, a hydrogenated polyoxyl castor oil, and octoxynol-
40, wherein the ophthalmic formulation is made by a method comprising the steps of:
25 a) mixing the cyclosporine with a hydrogenated polyoxyl castor oil at a temperature
of 55°C or above to form a mixture A; and
b) keeping mixture A under vacuum to remove foam;
c) optionally, lowering the temperature of mixture A to a temperature of 35°C±2°C
prior to the complete dissolution of the cyclosporine;
30 d) adding octoxynol-40; and
25
e) mixing the resulting mixture with the aqueous vehicle.
Preferably, mixing the cyclosporine with a hydrogenated polyoxyl castor oil is done at a
temperature of 55°C-60°C to form a mixture A. Optionally, mixture A is lowered to a
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with the hydrogenated polyoxyl 5 castor oil is done at a
temperature of 55°C±2°C to form a mixture A; and optionally lowering the temperature to
not higher than 35°C±2°C prior to the complete dissolution of the cyclosporine. Further,
the method comprises adding octoxynol-40 and then mixing the resulting mixture with an
aqueous vehicle at 35°C±2°C. In another aspect, the aqueous vehicle is mixed at a
10 temperature of 55±2°C.
Preferably, the hydrogenated polyoxyl castor oil is hydrogenated 40 polyoxyl castor oil
(HCO-40). More preferably, the ophthalmic formulation comprises 0.09 wt % of
cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt % of
octoxynol-40.
15 Another embodiment of the present disclosure is a stable nanomicellar ophthalmic
formulation comprising: cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40,
and an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
20 temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior
to the complete dissolution of the cyclosporine;
c) adding octoxynol-40; and
d) mixing the resulting mixture with the aqueous vehicle.
25 In one aspect, mixing the aqueous vehicle to a temperature of at 35°C±2°C. In another
aspect, mixing the aqueous vehicle to a temperature of 55±2°C.
In one embodiment, the present invention provides a stable nanomicellar ophthalmic
formulation comprising cyclosporine form with characteristic XRD peaks at 2-theta (deg.)
6.9, 7.8, 9.4 and 15.9.
26
In another embodiment, the present invention provides a stable nanomicellar ophthalmic
formulation comprising an amorphous form of cyclosporine.
Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising a cyclosporine, a hydrogenated polyoxyl
castor oil, and octoxynol-40, wherein the ophthalmic formulation 5 is made by a method
comprising the steps of: mixing the cyclosporine with a hydrogenated polyoxyl castor oil
at a temperature of 55°C or above to form a mixture A; and preventing the formation of
the cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 7.4, 8.7, 14.4 and
17.5 (B in Figure 2) by altering the temperature of mixture A prior to the complete
10 dissolution of the cyclosporine.
Preferably, mixing the cyclosporine with a hydrogenated polyoxyl castor oil is done at a
temperature of 55°C-60°C to form a mixture A. Further, mixture A is lowered to a
temperature of 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with the hydrogenated polyoxyl castor oil is done at a
15 temperature of 55°C±2°C to form a mixture A; and then mixture A is lowered to a
temperature not higher than 35°C±2°C prior to the complete dissolution of the
cyclosporine. In one aspect, the stable nanomicellar ophthalmic formulation comprises
cyclosporine with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 (A in
Fig.2). In another aspect, the stable nanomicellar ophthalmic formulation comprises an
20 amorphous form of cyclosporine. Further, the method comprises adding the octoxynol-40
and then mixing the resulting mixture with an aqueous vehicle at 35°C±2°C. In another
aspect, the resulting mixture is mixed with the aqueous vehicle at a temperature of
55±2°C. Preferably, the hydrogenated polyoxyl castor oil is hydrogenated 40 polyoxyl
castor oil (HCO-40). More preferably, the ophthalmic formulation comprises 0.09 wt % of
25 cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt % of
octoxynol-40.
Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising a cyclosporine, a hydrogenated polyoxyl
castor oil, and octoxynol-40, wherein the ophthalmic formulation is made by a method
30 comprising the steps of: mixing the cyclosporine with the hydrogenated polyoxyl castor
oil at a temperature of 55°C or above to form a mixture A; and preventing the formation of
the cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 8.5, 9.3, 11.6 and
27
20.3 (C in Figure 2) by altering the temperature of mixture A prior to the complete
dissolution of the cyclosporine.
Preferably, mixing the cyclosporine with a hydrogenated polyoxyl castor oil is done at a
temperature of 55°C-60°C to form a mixture A. Further, mixture A is then lowered to a
temperature of 35oC- 40°C prior to the complete dissolution 5 of the cyclosporine. More
preferably, mixing the cyclosporine with the hydrogenated polyoxyl castor oil is done at a
temperature of 55°C±2°C to form a mixture A; and then the temperature of mixture A is
lowered to a temperature not higher than 35°C±2°C prior to the complete dissolution of
the cyclosporine In one aspect, the method of making a stable nanomicellar ophthalmic
10 formulation comprises cyclosporine with characteristic XRD peaks at 2-theta (deg.) 6.9,
7.8, 9.4 and 15.9 (A in Figure 2). In another aspect, the method of making a stable
nanomicellar ophthalmic formulation comprises an amorphous form of cyclosporine.
Further, the method comprises adding octoxynol-40 and then mixing the resulting mixture
with an aqueous vehicle at 35°C±2°C. In another aspect, the aqueous vehicle is mixed at a
15 temperature of 55±2°C. Preferably, the hydrogenated polyoxyl castor oil is hydrogenated
40 polyoxyl castor oil (HCO-40). More preferably, the ophthalmic formulation comprises
0.09 wt % of cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt
% of octoxynol-40.
Another embodiment of the present disclosure is a method of making a stable
20 nanomicellar ophthalmic formulation comprising cyclosporine, a hydrogenated polyoxyl
castor oil, and octoxynol-40, wherein the ophthalmic formulation is made by a method
comprising the steps of: mixing the cyclosporine with hydrogenated polyoxyl castor oil at
a temperature of 55°C or above to form a mixture A; and applying vacuum to the mixture
to prevent the formation of the cyclosporine form with characteristic XRD peaks at 2-theta
25 (deg.) 7.4, 8.7, 14.4 and 17.5 (B in Figure 2).
Preferably, mixing the cyclosporine with hydrogenated polyoxyl castor oil is done at a
temperature of 55°C-60°C to form a mixture A. Optionally, the mixture A is lowered to a
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with the hydrogenated polyoxyl castor oil is done at a
30 temperature of 55°C±2°C to form a mixture A; optionally lowering to a temperature not
higher than 35°C±2°C prior to the complete dissolution of the cyclosporine. Further, the
method comprises adding the octoxynol-40 and then mixing the resulting mixture with an
aqueous vehicle at 35°C±2°C. In another aspect, the resulting mixture is mixed with the
28
aqueous vehicle at a temperature of 55±2°C. Preferably, cyclosporine is present in
cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 (A
in Figure 2). In another embodiment, preferably, cyclosporine is present in amorphous
form. Preferably, the hydrogenated polyoxyl castor oil is hydrogenated 40 polyoxyl castor
oil (HCO-40). More preferably, the ophthalmic formulation 5 comprises 0.09 wt % of
cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt % of
octoxynol-40.
Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising cyclosporine, a hydrogenated polyoxyl
10 castor oil, and octoxynol-40, wherein the ophthalmic formulation is made by a method
comprising the steps of: mixing the cyclosporine with hydrogenated polyoxyl castor oil at
a temperature of 55°C or above to form a mixture A; and applying vacuum to the mixture
to prevent the formation of the cyclosporine form with characteristic XRD peaks at 2-theta
(deg.) 8.5, 9.3, 11.6 and 20.3 (C in Figure 2).
15 Preferably, mixing the cyclosporine with hydrogenated polyoxyl castor oil is done at a
temperature of 55°C-60°C to form a mixture A. Optionally, the mixture A is lowered to a
temperature 35oC- 40°C prior to the complete dissolution of the cyclosporine. More
preferably, mixing the cyclosporine with hydrogenated polyoxyl castor oil is done at a
temperature of 55°C±2°C to form a mixture A; optionally lowering to a temperature not
20 higher than 35°C±2°C prior to the complete dissolution of the cyclosporine. Further, the
method comprises adding the octoxynol-40 and then mixing the resulting mixture with an
aqueous vehicle at 35°C±2°C. In another aspect, the resulting mixture is mixed with the
aqueous vehicle at a temperature of 55±2°C. Preferably, cyclosporine is present in
cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 (A
25 in Figure 2). In another embodiment, preferably, cyclosporine is present in amorphous
form. Preferably, the hydrogenated polyoxyl castor oil is hydrogenated 40 polyoxyl castor
oil (HCO-40). More preferably, the ophthalmic formulation comprises 0.09 wt % of
cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt % of
octoxynol-40.
30 Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising:
cyclosporine, hydrogenated polyoxyl castor oil, octoxynol-40, and an aqueous vehicle,
wherein the method comprising the steps of:
29
a) mixing the cyclosporine with the hydrogenated polyoxyl castor oil at a temperature
of 127-130°C until completely dissolved to form a mixture A;
b) adding octoxynol-40 to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of at 127-
5 130°C;
wherein, cyclosporine is present in a form having characteristic XRD peaks at 2-theta
(deg.) 7.4, 8.7, 14.4 and 17.5 (B in Figure 2).
Preferably, the hydrogenated polyoxyl castor oil is hydrogenated 40 polyoxyl castor oil
(HCO-40). More preferably, the ophthalmic formulation comprises 0.09 wt % of
10 cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt % of
octoxynol-40.
Another embodiment of the present disclosure is a method of making a stable
nanomicellar ophthalmic formulation comprising:
cyclosporine, hydrogenated polyoxyl castor oil, octoxynol-40, and an aqueous vehicle,
15 wherein the method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated polyoxyl castor oil at a temperature
of 127-130°C until completely dissolved to form a mixture A;
b) adding octoxynol-40 to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of 127-
20 130°C,
wherein, cyclosporine is present in a form with characteristic XRD peaks at 2-theta (deg.)
8.5, 9.3, 11.6 and 20.3 (C in Figure 2). Preferably, the hydrogenated polyoxyl castor oil is
hydrogenated 40 polyoxyl castor oil (HCO-40). More preferably, the ophthalmic
formulation comprises 0.09 wt % of cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl
25 castor oil, and 0.05 wt % of octoxynol-40.
In yet another embodiment of the present disclosure is a stable nanomicellar ophthalmic
formulation comprising:
cyclosporine, hydrogenated polyoxyl castor oil, octoxynol-40, and an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
30
a) mixing the cyclosporine with the hydrogenated polyoxyl castor oil at a temperature
of 127-130°C until completely dissolved to form a mixture A;
b) adding octoxynol-40 to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of at 127-
5 130°C;
wherein, cyclosporine is present in a form having characteristic XRD peaks at 2-theta
(deg.) 7.4, 8.7, 14.4 and 17.5 (B in Figure 2).
Preferably, the hydrogenated polyoxyl castor oil is hydrogenated 40 polyoxyl castor oil
(HCO-40). More preferably, the ophthalmic formulation comprises 0.09 wt % of
10 cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt % of
octoxynol-40.
In yet another embodiment of the present disclosure is a stable nanomicellar ophthalmic
formulation comprising:
cyclosporine, hydrogenated polyoxyl castor oil, octoxynol-40, and an aqueous vehicle,
15 wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated polyoxyl castor oil at a temperature
of 127-130°C until completely dissolved to form a mixture A;
b) adding octoxynol-40 to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of 127-
20 130°C,
wherein, cyclosporine is present in a form with characteristic XRD peaks at 2-theta (deg.)
8.5, 9.3, 11.6 and 20.3 (C in Figure 2). Preferably, the hydrogenated polyoxyl castor oil is
hydrogenated 40 polyoxyl castor oil (HCO-40). More preferably, the ophthalmic
formulation comprises 0.09 wt % of cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl
25 castor oil, and 0.05 wt % of octoxynol-40.
Another embodiment of the present disclosure is a stable nanomicellar ophthalmic
formulation comprising cyclosporine, a hydrogenated 40 polyoxyl castor oil (HCO-40),
and octoxynol-40, wherein the formulation is a solution; and the formulation exhibits
stability at room temperature (20-25oC) for 6 to at least 24 months. Typically, the
30 ophthalmic formulations are stable when maintained at room temperature for at least 6
31
months, at least 8 months, at least 10 months, at least 12 months, at least 14 months, at
least 16 months, at least 18 months, at least 20 months and at least 24 months. More
preferably, the stable nanomicellar ophthalmic formulation is a solution and comprises
0.09 wt % of cyclosporine, 1.0 wt % of hydrogenated 40 polyoxyl castor oil, and 0.05 wt
5 % of octoxynol-40.
Another embodiment of the present disclosure is a method of treating or preventing an
ocular disease or condition, the method comprising administering a stable nanomicellar
ophthalmic formulation comprising 0.09 wt % of cyclosporine, 1.0 wt % of hydrogenated
40 polyoxyl castor oil, and 0.05 wt % of octoxynol-40 after 6 to at least 24 months of the
10 manufacture of the formulation to a patient in need thereof.
The cyclosporine present in certain formulations according to embodiments of this
disclosure is preferably amorphous when it is in solution. Alternatively, the cyclosporine
may be present as a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9,
7.8, 9.4 and 15.9 in solution. In certain embodiments, there is no crystalline cyclosporine
15 present in a solution according to the present disclosure. In certain embodiment, the
formulations according to embodiments of this disclosure is substantially free of a
cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 7.4, 8.7, 14.4 and 17.5.
In alternative embodiments, the formulations according to this disclosure are substantially
free of a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 8.5, 9.3, 11.6
20 and 20.3.
Additional Formulation Ingredients
The compositions of the present disclosure may also contain other components such as,
but not limited to, additives, adjuvants, buffers, tonicity agents, bioadhesive polymers, and
preservatives. In any of the compositions of this disclosure for topical to the eye, the
25 mixtures are preferably formulated at about pH 5 to about pH 8. This pH range may be
achieved by the addition of buffers to the composition as described in the examples. In an
embodiment, the pH range in the composition in a formulation is about pH 6.5 to about pH
7.2. It should be appreciated that the compositions of the present disclosure may be
buffered by any common buffer system such as phosphate, borate, acetate, citrate,
30 carbonate and borate-polyol complexes, with the pH and osmolality adjusted in
accordance with well-known techniques to proper physiological values. The mixed
micellar compositions of the present disclosure are stable in buffered aqueous solution.
32
That is, there is no adverse interaction between the buffer and any other component that
would cause the compositions to be unstable.
Tonicity agents include, for example, mannitol, sodium chloride, sodium nitrate, sodium
sulfate, dextrose, xylitol or combinations thereof. These tonicity agents may be used to
adjust the osmolality of the compositions. In an aspect, the osmolality 5 of the formulation is
adjusted to be in the range of about 150 to about 200 mOsmol/kg. In a preferred aspect,
the osmolality of the formulation is adjusted to between about 160 to about 190
mOsmol/kg.
An additive such as a sugar, a glycerol, and other sugar alcohols, can be included in the
10 compositions of the present disclosure. Pharmaceutical additives can be added to increase
the efficacy or potency of other ingredients in the composition. For example, a
pharmaceutical additive can be added to a composition of the present disclosure to
improve the stability of the calcineurin inhibitor, to adjust the osmolality of the
composition, to adjust the viscosity of the composition, or for another reason, such as
15 effecting drug delivery. Non-limiting examples of pharmaceutical additives of the present
disclosure include sugars, such as, trehalose, mannose, D-galactose, and lactose. In an
embodiment, the sugars can be incorporated into a composition prior to hydrating the thin
film (i.e. internally). In another embodiment, the sugars can be incorporated into a
composition during the hydration step (i.e. externally). In an embodiment, an aqueous,
20 clear, mixed micellar solution of the present disclosure includes additives such as sugars.
In an embodiment, compositions of the present disclosure further comprise one or more
bioadhesive polymers. Bioadhesion refers to the ability of certain synthetic and biological
macromolecules and hydrocolloids to adhere to biological tissues. Bioadhesion is a
complex phenomenon, depending in part upon the properties of polymers, biological
25 tissue, and the surrounding environment. Several factors have been found to contribute to
a polymer's bioadhesive capacity: the presence of functional groups able to form hydrogen
bridges (--OH, COOH), the presence and strength of anionic charges, sufficient elasticity
for the polymeric chains to interpenetrate the mucous layer, and high molecular weight.
Bioadhesion systems have been used in dentistry, orthopedics, ophthalmology, and in
30 surgical applications. However, there has recently emerged significant interest in the use
of bioadhesive materials in other areas such as soft tissue-based artificial replacements,
and controlled release systems for local release of bioactive agents. Such applications
33
include systems for release of drugs in the buccal or nasal cavity, and for intestinal or
rectal administration.
In an embodiment, a composition of the present disclosure includes at least one
bioadhesive polymer. The bioadhesive polymer can enhance the viscosity of the
composition and thereby increase residence time in the eye. Bioadhesive 5 polymers of the
present disclosure include, for example, carboxylic polymers like Carbopol® (carbomers),
Noveon® (polycarbophils), cellulose derivatives including alkyl and hydroxyalkyl
cellulose like methylcellulose, hydroxypropylcellulose, carboxymethylcellulose, gums like
locust beam, xanthan, agarose, karaya, guar, and other polymers including but not limited
10 to polyvinyl alcohol, povidone, polyethylene glycol, Pluronic® (Poloxamers), tragacanth,
and hyaluronic acid; phase-transition polymers for providing sustained and controlled
delivery of enclosed medicaments to the eye (e.g., alginic acid, carrageenans (e.g.,
Eucheuma), xanthan and locust bean gum mixtures, pectins, cellulose acetate phthalate,
alkylhydroxyalkyl cellulose and derivatives thereof, hydroxyalkylated polyacrylic acids
15 and derivatives thereof, poloxamers and their derivatives, etc. Physical characteristics in
these polymers can be mediated by changes in environmental factors such as ionic
strength, pH, or temperature alone or in combination with other factors. In an embodiment,
the optional one or more bioadhesive polymers is present in the composition from about
0.01 wt % to about 10 wt %/volume, preferably from about 0.1 to about 5 wt %/volume.
20 In an embodiment, the compositions of the present disclosure further comprise at least one
hydrophilic polymer excipient selected from, for example, PVP-K-30, PVP-K-90, HPMC,
HEC, and polycarbophil. In an embodiment, the polymer excipient is selected from PVPK-
90, PVP-K-30 or HPMC. In an embodiment, the polymer excipient is selected from
PVP-K-90 or PVP-K-30.
25 In an embodiment, if a preservative is desired, the compositions may optionally be
preserved with any of many well-known preservatives, including benzyl alcohol
with/without EDTA, benzalkonium chloride, chlorhexidine, Cosmocil® CQ, or Dowicil®
200. In certain embodiments, it may be desirable for a formulation as described herein to
not include any preservatives. In this regard, preservatives may in some embodiments not
30 be necessary or desirable in formulations included in single use containers. In other
embodiments, it may be advantageous to include preservatives, such as in certain
embodiments in which the formulations are included in a multiuse container.
34
In a preferable embodiment, the present disclosure relates to a method of making a stable
nanomicellar ophthalmic formulation comprising:
0.09 wt % of cyclosporine
about 1.0 wt % of hydrogenated 40 polyoxyl castor oil,
about 5 0.05 wt % of octoxynol-40, and
an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
10 b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior to the
complete dissolution of the cyclosporine, adding octoxynol-40; and
c) mixing the resulting mixture with the aqueous vehicle.
In another preferable embodiment, the present disclosure relates to a method of making a
stable nanomicellar ophthalmic formulation comprising:
15 0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40, and
an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
20 a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) keeping mixture A under vacuum to remove foam;
c) optionally, lowering the temperature of mixture A to a temperature of 35°C±2°C
prior to the complete dissolution of the cyclosporine;
25 d) adding octoxynol-40; and
e) mixing the resulting mixture with the aqueous vehicle.
In one aspect, mixing the aqueous vehicle at a temperature of at 35°C±2°C. In another
aspect, mixing the aqueous vehicle at a temperature of 55±2°C.
35
The stable nanomicellar ophthalmic formulation of preceding embodiments further
comprises:
about 0.20-0.550 wt % sodium phosphate monobasic,
about 0.23-0.465 wt % sodium phosphate dibasic,
5 about 0.05 wt % sodium chloride,
about 0.3 wt % povidone,
sodium hydroxide/hydrochloric acid to adjust the pH, and
water for injection.
In another preferable embodiment, the present disclosure is a stable nanomicellar
10 ophthalmic formulation, wherein the pH of the formulation is about 5.0 to 8.0. More
preferably, the pH of the formulation is about 6.5 to 7.2.
Further, the present invention disclosure is a stable nanomicellar ophthalmic formulation
wherein the osmolality of the formulation is between about 150 to about 200 mOsmol/kg.
Further, the present invention disclosure is a stable nanomicellar ophthalmic formulation
15 wherein the mixed nanomicellar size and polydispersity index are determined with
Zetasizer, Malvern Instruments, N.J. In brief, approximately 1 ml of each formulation was
transferred to a cuvette and placed in the instrument. A laser beam of light was used to
determine the mixed nanomicellar size. Nanomicelles contemplated by the present
disclosure typically have a particle size in the range of about 1-100 nm; in some
20 embodiments, the particle size falls in the range of about 5-50 nm; in some embodiments,
the particle size falls in the range of about 10-40 nm; in some embodiments, the particle
size is about 13-16 nm.
In another embodiment, the present disclosure relates to a cyclosporine form with
characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9.
25 In yet another embodiment, the present disclosure relates to a stable nanomicellar
ophthalmic formulation comprising an amorphous form of cyclosporine.
In yet another embodiment, the present disclosure relates to a stable nanomicellar
ophthalmic formulation, wherein the formulation is substantially free of a cyclosporine
form with characteristic XRD peaks at 2-theta (deg.) 7.4, 8.7, 14.4 and 17.5.
36
In yet another embodiment, the present disclosure is a stable nanomicellar ophthalmic
formulation, wherein the formulation is substantially free of a cyclosporine form with
characteristic XRD peaks at 2-theta (deg.) 8.5, 9.3, 11.6 and 20.3.The XRD data for these
cyclosporine forms are presented in Figure 2.
The compete dissolution time of cyclosporine depends on quantity 5 of the cyclosporine A
to be dissolved based on the batch size. Generally dissolution time of cyclosporine in
hydrogenated 40 polyoxyl castor oil (KOLLIPHOR RH 40) at a ratio of 9:10
(cyclosporine : KOLLIPHOR RH 40) was found to be not less than 130 minutes. The
cyclosporine A slowly dissolved over a period of time with stirring and during this
10 complete dissolution period, the solution became clear. If the cyclosporine A reprecipitates
during the dissolution period, there is a chance that a slight turbid solution
might have been transferred to the aqueous phase during manufacturing of the batch. This
may initiate a seeding effect for crystal growth in the final formulation during storage,
which may lead to batch failure. Based on these observations, the solubility behavior of
15 cyclosporine was studied in hydrogenated 40 polyoxyl castor oil (Kolliphor RH 40) at
55oC and 35°C. It was found that the solution stability at 35°C was comparatively higher
than the solution stability at 55°C (see Example 2 in Table 4). Based on the above
observation it is believed that if cyclosporine was not completely dissolved in Kolliphor
RH 40 at 55°C, the temperature can be reduced to 35°C. This is because the solution
20 stability of cyclosporine at 35°C was higher than that of 55°C.
In another aspect, when the cyclosporine is present in a form having characteristic XRD
peaks at 2-theta (deg.) 7.4, 8.7, 14.4 and 17.5 (B in Figure 2), the mixing of the
cyclosporine with the hydrogenated polyoxyl castor oil is done at a temperature of 127-
130°C until completely dissolved and octoxynol-40 is added to this to mixture at 127-
25 130°C.
In another aspect, when the cyclosporine is present in a form having characteristic XRD
peaks at 2-theta (deg.) 8.5, 9.3, 11.6 and 20.3 (C in Figure 2)., the mixing of the
cyclosporine with the hydrogenated polyoxyl castor oil is done at a temperature of 127-
130°C until completely dissolved and octoxynol-40 is added to this to mixture at 127-
30 130°C.
In certain aspects of the present invention, in the step of lowering the temperature of
mixture A, mixture A is lowered to a temperature of 35°C±2°C. The step of lowering the
37
temperature of mixture A may occur in less than 65 minutes. Preferably, at about 60 mins.
In certain aspects, water may be added after the step of lowering the temperature of
mixture A.
In another aspect, the present disclosure relates to a stable nanomicellar ophthalmic
formulation, prepared by a method c 5 omprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior to the
complete dissolution of the cyclosporine;
10 c) adding octoxynol-40; and
d) then mixing the resulting mixture with an aqueous vehicle at 35°C±2°C, wherein
the mixture A is lowered to a temperature of 35°C±2°C in less than 65 minutes.
Preferably, the mixture A is lowered to a temperature of 35°C±2°C in 60 minutes.
In one aspect, mixing the mixture A of step (a) for 20-30 minutes. Preferably, 20-25
15 minutes, more preferably, mixing the mixture A of step (a) for 20 ±2 minutes.
In one aspect, lowering the temperature of to 35°C±2°C and stirring for 60-70 minutes.
Preferably, stirring the mixture for 60±5 minutes at a temperature of 35°C±2°C.
In yet another aspect, the present invention relates to a method of making a stable
nanomicellar ophthalmic formulation comprising:
20 0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40,
about 0.20-0.550 wt % sodium phosphate monobasic,
about 0.23-0.465 wt % sodium phosphate dibasic,
25 about 0.05 wt % sodium chloride,
about 0.3 wt % povidone,
sodium hydroxide/hydrochloric acid to adjust the pH, and
water for injection,
wherein the method comprising the steps of:
38
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior to the
complete dissolution of the cyclosporine, adding octoxynol-40 to form an API
5 mixture;
c) adding API mixture to Water for Injection (WFI);
d) adding remaining excipients to step (c) in the order of sodium phosphate
monobasic, then sodium phosphate dibasic, then sodium chloride, and then
polyvinylpyrrolidone;
10 e) adjusting the pH to 6.5 to 7.2 and bringing to the final volume with WFI.
In one aspect, mixing cyclosporine in step (a) at 200-300 RPM.
In one aspect, mixing the mixture A of step (a) for 20-30 minutes. Preferably, 20-25
minutes, more preferably, mixing the mixture A of step (a) for 20 ±2 minutes.
In one aspect, lowering the temperature of the mixture A to 35°C±2°C in less than 65
15 minutes. Preferably, lowering the temperature of the mixture A to 35°C±2°C in 40-50
minutes.
In another aspect, stirring the mixture of step (b) for 60-70 minutes. Preferably, stirring the
mixture for 60±5 minutes at a temperature of 35°C±2°C.
In one aspect, mixing the API mixture to WFI at a temperature of 35°C±2°C. In another
20 aspect, mixing the API mixture to WFI at a temperature of 55±2°C.
In yet another aspect, the present invention relates to a method of making a stable
nanomicellar ophthalmic formulation comprising:
0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
25 about 0.05 wt % octoxynol-40,
about 0.20-0.550 wt % sodium phosphate monobasic,
about 0.23-0.465 wt % sodium phosphate dibasic,
about 0.05 wt % sodium chloride,
about 0.3 wt % povidone,
39
sodium hydroxide/hydrochloric acid to adjust the pH, and
water for injection,
wherein the method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°5 C±2°C or above to form a mixture A;
b) keeping mixture A under vacuum to remove foam;
c) optionally, lowering the temperature of mixture A to a temperature of
35°C±2°C prior to the complete dissolution of the cyclosporine;
d) adding octoxynol-40;
10 e) adding API mixture to Water for Injection (WFI);
f) adding remaining excipients to step (c) in the order of sodium phosphate
monobasic, then sodium phosphate dibasic, then sodium chloride, and then
polyvinylpyrrolidone; and
g) adjusting the pH to 6.5 to 7.2 and bringing to the final volume with WFI.
15 In one aspect, mixing the mixture A of step (a) for 20-30 minutes. Preferably, 20-25
minutes, more preferably, mixing the mixture A of step (a) for 20 ±2 minutes.
In one aspect, lowering the temperature of the mixture A to 35°C±2°C in less than 65
minutes. Preferably, lowering the temperature of the mixture A to 35°C±2°C in 40-50
minutes.
20 In one aspect, mixing the API mixture to WFI at a temperature of 35°C±2°C. In another
aspect, mixing the API mixture to WFI at a temperature of 55±2°C.
In a more preferred aspect, the present invention provides for a stable nanomicellar
ophthalmic formulation prepared by any of the method as described above.
In yet another aspect, the present disclosure relates to a stable nanomicellar ophthalmic
25 formulation comprising:
0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40, and
40
an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 127-130°C until completely dissolved to form a mixture A;
b) adding octoxynol-5 40 to mixture A at 127-130°C; and
c) mixing the resulting mixture with the aqueous vehicle at a temperature of at
127-130°C,
wherein, cyclosporine is present in a form having characteristic XRD peaks at 2-theta
(deg.) 7.4, 8.7, 14.4 and 17.5.
10 In yet another aspect, the present disclosure relates to a stable nanomicellar ophthalmic
formulation comprising:
0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40, and
15 an aqueous vehicle,
wherein the ophthalmic formulation is made by a method comprising the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 127-130°C until completely dissolved to form a mixture A;
b) adding octoxynol-40 to mixture A at 127-130°C; and
20 c) mixing the resulting mixture with the aqueous vehicle at a temperature of
127-130°C,
wherein, cyclosporine is present in a form with characteristic XRD peaks at 2-theta (deg.)
8.5, 9.3, 11.6 and 20.3.
In one embodiment, the mixing speed, time and energy input plays a role in the complete
25 dissolution of cyclosporine in hydrogenated polyoxyl castor oil. When low speed is used,
time is increased for dissolution, In one aspect of the embodiment, typically cyclosporine
is dissolved hydrogenated polyoxyl castor oil by stirring at approximately 200-300 RPM
for 75 minutes, for 70 minutes, for 65minutes, for 60 minutes, for 55 minutes, for 50
minutes, for 45 minutes, for 40 minutes, for 35 minutes, for 30 minutes, for 25 minutes,
41
for 20 minutes, for 15 minutes, for 10 minutes. In another aspect, typically cyclosporine is
dissolved hydrogenated polyoxyl castor oil by stirring at approximately 300-400 RPM for
65minutes, for 60 minutes, for 55 minutes, for 50 minutes, for 45 minutes, for 40 minutes,
for 35 minutes, for 30 minutes, for 25 minutes, for 20 minutes, for 15 minutes, for 10
minutes. In another aspect, typically cyclosporine is dissolved 5 hydrogenated polyoxyl
castor oil by stirring at approximately 350-400 RPM for 60 minutes, for 55 minutes, for 50
minutes, for 45 minutes, for 40 minutes, for 35 minutes, for 30 minutes, for 25 minutes,
for 20 minutes, for 15 minutes, for 10 minutes. In another aspect, typically cyclosporine is
dissolved hydrogenated polyoxyl castor oil by stirring at approximately 400-450 RPM for
10 50 minutes, for 45 minutes, for 40 minutes, for 35 minutes, for 30 minutes, for 25 minutes,
for 20 minutes, for 15 minutes, for 10 minutes. In another aspect, typically cyclosporine is
dissolved hydrogenated polyoxyl castor oil by stirring at approximately >450 RPM for 40
minutes, for 35 minutes, for 30 minutes, for 25 minutes, for 20 minutes, for 15 minutes,
for 10 minutes, for 5 minutes. In yet another aspect, cyclosporine is dissolved
15 hydrogenated polyoxyl castor oil by stirring at approximately 200-300 RPM till complete
dissolution.
The energy input into the mixture is defined in Equation 1 as:
E/V=n3D5t/V (1)
wherein E is the theoretical energy input, n is the shear plate rpm, D is the shear plate
20 diameter, t is the time, and V is the solution volume. The energy input per volume is scale
independent. (Diaz, M., et al., “Mixing Power, External Convection, and Effectiveness in
Bioreactors,” Biotechnology and Bioengineering, Vol. 51, 1996, pp. 131-140). This is a
simple, rapid and reliable way to scale up the preparation of the nanomicellar formulation.
Alternative methods of mixing, such as the use of sonicators, or the use of solvents, water,
25 or pressure, may be used to impact the temperatures or times of the respective method
steps. For example, if solvents are used, it may be possible to utilize lower temperatures
in the method steps.
The instant disclosure further relates to treating or preventing ocular diseases or disorders,
for example, by local administration of the formulations as described herein.
30 The term “treating” refers to: preventing a disease, disorder or condition from occurring in
a cell, a tissue, a system, animal or human which may be predisposed to the disease,
disorder and/or condition but has not yet been diagnosed as having it; stabilizing a disease,
42
disorder or condition, i.e., arresting its development; and/or relieving one or more
symptoms of the disease, disorder or condition, i.e., causing regression of the disease,
disorder and/or condition.
As used herein, a composition that “prevents” a disorder or condition refers to a compound
that, in a statistical sample, reduces the occurrence 5 of the disorder or condition in the
treated sample relative to an untreated control sample, or delays the onset or reduces the
severity of one or more symptoms of the disorder or condition relative to the untreated
control sample.
As used herein, the term “ocular disease” refers to diseases/conditions of the eye(s) that
10 can be sight threatening, lead to eye discomfort, and may signal systemic health problems.
A patient or subject to be treated by any of the compositions or methods of the present
disclosure can mean either a human or a non-human animal. In an embodiment, the
present disclosure provides methods for the treatment of an ocular disease in a human
patient in need thereof. In an embodiment, the present disclosure provides methods for the
15 treatment of an inflammatory ocular disease in a human patient in need thereof. In another
embodiment, the present disclosure provides methods for the treatment of an ocular
disease in a veterinary patient in need thereof, including, but not limited to dogs, horses,
cats, rabbits, gerbils, hamsters, rodents, birds, aquatic mammals, cattle, pigs, camelids, and
other zoological animals.
20 In some embodiments of the compositions and methods disclosed herein, the cyclosporine
further comprises one or more additional active ingredients, e.g., active agents selected
from the group consisting of a resolvin or resolvin-like compound, a steroid (such as a
corticosteroid), and the like. In some embodiments, the additional active agent includes a
resolvin. In some embodiments, the additional active agent includes a corticosteroid. In
25 some embodiments, the additional active agent includes a resolvin and a corticosteroid. In
some embodiments, the additional active agent includes an antibiotic, for example one or
more antibiotics selected from the group consisting of azythromycin, ciprofloxacin,
ofloxacin, gatifloxacin, levofloxacin, moxifloxacin, besifloxacin, and levofloxacin. In
some embodiments, the additional active agent includes an antibiotic, for example one or
30 more antibiotics selected from the group consisting of azythromycin, ciprofloxacin,
ofloxacin, gatifloxacin, levofloxacin, moxifloxacin, besifloxacin, and levofloxacin; and a
second of such agents is a resolvin such as described herein (including without limitation
43
compound 1001). In some embodiments, the active agent includes two or more active
agents and one of said active agents is an antiviral, for example one or more antivirals
selected from the group consisting of ganciclovir, trifluridine, acyclovir, famciclovir,
valacyclovir, penciclovir and cidofovir. In some embodiments, the active agent includes
two or more active agents and one of the active agents is an antibiotic, 5 for example one or
more antivirals selected from the group consisting of ganciclovir, trifluridine, acyclovir,
famciclovir, valacyclovir, penciclovir and cidofovir; and a second of the active agents is a
resolvin such as described herein (including without limitation compound 1001).
Accordingly, in another aspect, provided is a method treating or preventing an ocular
10 disease or condition that includes locally administering a formulation of any of the aspects
or embodiments as disclosed herein. In some embodiments, the ocular disease is an
anterior segment disease. In some embodiments, the ocular disease is a posterior segment
disease. In some embodiments, the ocular disease is one or more selected from the group
consisting of dry eye syndrome, Sjogren’s syndrome, uveitis, anterior uveitis (iritis),
15 chorioretinitis, posterior uveitis, conjunctivitis, allergic conjunctivitis, keratitis,
keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis,
systemic immune mediated diseases such as cicatrizing conjunctivitis and other
autoimmune disorders of the ocular surface, blepharitis, scleritis, age-related macular
degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), ocular
20 neovascularization, age-related macular degeneration (ARMD), proliferative
vitreoretinopathy (PVR), cytomegalovirus (CMV) retinitis, optic neuritis, retrobulbar
neuritis, and macular pucker. In one embodiment, the ocular disease is dry eye. In one
embodiment, the ocular disease is allergic conjunctivitis. In one embodiment. the ocular
disease is age-related macular degeneration (AMD). In one embodiment, the ocular
25 disease is diabetic retinopathy.
The daily dose of the ophthalmic formulation, effective to reduce dry eye symptoms
and/or to improve tear film can be divided among one or several unit dose administrations.
A subject would use the product as needed, but generally, this would not be more than
twice a day and in many instances the product would be used only once a day. A preferred
30 regimen for the nanomicellar ophthalmic formulation of the present invention is one drop
of 0.09% (w/w) solution per eye twice a day (approximately 12 hours apart).
EXAMPLES
44
To illustrate non-limiting embodiments of the present disclosure, the following Examples
were prepared.
EXAMPLE 1
Table 1: Cyclosporine nanomicellar ophthalmic formulation
Ingredients Amount
Cyclosporine 0.09 wt %
hydrogenated 40 polyoxyl castor oil, 1.0 wt %
octoxynol-40 0.05 wt %
sodium phosphate monobasic, 0.53 wt %
sodium phosphate dibasic, 0.47 wt %
sodium chloride, 0.05 wt %
povidone, 0.3 wt %
sodium hydroxide q.s. to adjust pH, if required
hydrochloric acid q.s. to adjust pH, if required
water for injection q.s. to 100%
Cyclosporine nanomicellar ophthalmic solutions were prepared 5 as follows. In Example
1(a), polyoxyl 40 hydrogenated castor oil (KOLLIPHOR RH 40) was melted at 55-60°C
with stirring at around 200 rpm. Cyclosporine A was added to the melted Kolliphor RH
40 at 55-60°C and the reaction mixture was mixed at the same temperature range until
complete dissolution. Following solubilization of the cyclosporine A, a surfactant
10 (octoxynol-40) was added under stirring and after 10 minutes of stirring, this non-aqueous
solution was delivered at 55-60°C to 90% water for injection. The temperature of the
water for injection was maintained at < 22°C. Sodium phosphate monobasic, sodium
phosphate dibasic, sodium chloride and povidone, were added to the bulk solution
sequentially under stirring until complete dissolution. Once all ingredients were
15 completely solubilized in the bulk solution, the volume was made up to 100% with water
for injection to 1 L. In Example 1(b), the procedures of Example 1(a) were followed, with
the exception that the cyclosporine A solution in KOLLIPHOR RH 40 at 55-60°C was
added to water just after it started showing turbidity.
The batches of both Examples 1(a) and 1(b) were filled into 3 piece 5 mL low density
20 polyethlylene (“LDPE”) vials in an aseptic area. The vials were exposed to accelerated
temperatures of 40 °C and 30 °C in chambers (to accelerate particulate formation). The
samples were visually observed daily to see any sign of turbidity and/or visible particle
formation. The two batches were analyzed for critical quality parameters, such as, an
assay of cyclosporine, pH, osmolality, and micelle size, for which all was found well
45
within specification. The results are given in Table 2 below. Figure 1 shows photographs
of the stable batch (Example 1a) and the unstable batch (Example 1b).
Table 2
Stability Condition Example 1 (a) Example 1 (b)
30 °C
Particle/turbidity formation
at 25 days
Particle/turbidity formation
at 11 days
Critical Quality Attributes
Assay of Cyclosporine 100.05 100.10
Total impurities 0.470 0.649
Ph 6.86 6.79
Osmolality 167 171
Particle Size
Z avg
16.29 16.95
PDI 0.148 0.172
The data in Table 2 illustrates that that when the batch is manufactured 5 using a clear CsA
non-aqueous phase (cyclosporine in KOLLIPHOR RH 40 and octoxynol-40) and then
adding the mixture to a water phase, the batch remains stable for a longer time. However,
when the batch is manufactured using a turbid cyclosporine non-aqueous phase and then
adding the mixture to the water phase, the batch shows lower stability. This demonstrates
10 that a heterogeneous distribution of cyclosporine within micelles might facilitate
nucleation and particle formation in a finished product upon storage.
EXAMPLE 2
The solution stability of cyclosporine A lots in polyoxyl 40 hydrogenated castor oil
15 (KOLLIPHOR RH 40) at 55-60°C is an important process parameter for a stable
formulation. It was also surprisingly found that the solubility behavior varied over the time
of the storage, as shown in Table 3.
Table 3: Solution stability of cyclosporine in KOLLIPHOR RH 40 at 55°C
Parameter
Solution stability of CsA in Kolliphor RH 40 at 55°C
Initial data at
receipt of the
API
Current data
Study Study 1 Study 2 Study 3 Study 4 Study 5
Time to dissolve at
55°C (min)
20-30 45 40 165# 63 62
46
Total time for which the
solution remains clear
at 55°C (min) after API
is totally dissolved
(acceptance criteria is
NLT 75 min)
81*
60 90 7 99 102
52*
* Average of three studies results. # Some undissolved particles remained for a long time and
solution started to become slightly hazy very fast after complete solubility.
EXAMPLE 3
Similarly, the solubility behavior study of cyclosporine A in polyoxyl 5 40 hydrogenated
castor oil (KOLLIPHOR RH 40) was tested at 35°C. Table 4 shows the results of a
solubility behavior study of cyclosporine A in KOLLIPHOR RH 40 at 35°C. As can be
seen from Table 4, it was found that the solution stability at 35°C was comparatively
higher than the solution stability at 55°C.
10 Table 4: Comparative solution stability of cyclosporine A in amorphous form in
KOLLIPHOR RH 40 at 35°C and 55°C
Lot No. of CsA
35°C 55°C
Solution stability
at 35°C
SD
Solution stability
at 55°C
SD
Lot 7 239 10 92.17 14.77
Lot 8 304 12 99.33 4.62
Lot 9 248 17 79.67 9.29
Lot 10 125 0 49.67 17.79
Lot 11 62 0 23.25 1.50
Lot 12 235 7.64 74.33 4.93
Lot 17 135 0 46 0.00
Lot 18 114 0 44 0.00
Lot 19 80 0 47 0.00
As can be seen from Table 4, if cyclosporine A was not completely dissolved in
KOLLIPHOR RH 40 at 55°C, the temperature can be reduced to 35°C. Based on this data,
15 it is believed that the solution stability of cyclosporine A at 35°C was higher than that of
55°C. The complete dissolution stage of cyclosporine A in KOLLIPHOR RH 40 was
modified as follows:
(i) API was dispersed at 55°C±2°C for 20 min and stirred for another 15 minutes;
47
(ii) the temperature was then decreased to 35°C±2°C from 55°C±2°C in less than
55 min (about 40 min), and the solution was stirred at 35°C±2°C until complete
dissolution of the API was achieved; and
(iii) octoxynol-40 was added with stirring and the non-aqueous phase was
delivered to water f 5 or injection at 35°C±2°C.
The changes in this dissolution process can accommodate lot to lot variability of
the solution stability of API in Kolliphor RH-40 at 55 °C and also variability during the
storage as well.
10 EXAMPLE 4
The solubility behavior of three cyclosporine forms as disclosed in Figure 2 were
studied in polyoxyl 40 hydrogenated castor oil (KOLLIPHOR RH 40) at 55°C. The
results are shown in Table 5.
Table 5: Solubility of cyclosporine in KOLLIPHOR RH40 at 55 °C
Parameters
studied
API type
CsA form with
characteristic
XRD peaks at 2-
theta (deg.) 6.9,
7.8, 9.4 and 15.9.
CsA form with
characteristic XRD
peaks at 2-theta
(deg.) 7.4, 8.7, 14.4
and 17.5
CsA form with
characteristic
XRD peaks at 2-
theta (deg.) 8.5,
9.3, 11.6 and
20.3.
Amorphous
API
Time taken to
dissolve at
55°C (min.)
15 14 min with haziness
15 min with
haziness
8
Time at which
haziness
appears (min.)
130 NA NA 92
15
Figures 3(a) to 3(d) are photographs of the results of the study reported in Table 5.
As can be seen from the Table 5 above and from the associated figures, the CsA form with
characteristic XRD peaks at 2-theta (deg.) 7.4, 8.7, 14.4 and 17.5 and the CsA form with
characteristic XRD peaks at 2-theta (deg.) 8.5, 9.3, 11.6 and 20.3 have much less solubility
20 as compared to the CsA form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4
and 15.9. During dissolution of cyclosporine in KOLLIPHOR RH 40 at 55°C, the CsA
48
form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 may change
into less soluble forms, or amorphous cyclosporine may recrystallize into comparatively
less soluble forms. This conversion may be dependent on stresses to the system, including
temperature, long storage times at higher temperatures, and the like. To this end, the
cyclosporine ophthalmic formulation was exposed to higher temperatures 5 and times and
PXRD data was taken from the precipitated part; it was found that the precipitate was
close to the CsA form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and
15.9, as shown in Figure 4. Because this CsA form has lower solubility in water, its use
may lead to a seeding effect either at the initial stage or during storage at higher
10 temperatures, thus leading to batch failure.
In another attempt, the behavior of CsA in Kolliphore RH 40 alone in absence of water is
determined. The CsA was dissolved in Kolliphore RH 40 at 55°C and kept it for a longer
time till the precipitation occurred. The precipitated part was separated out and PXRD was
done. It was found that the cyclosporine has characteristic XRD peaks at 2-theta (deg.)
15 8.5, 9.3, 11.6 and 20.3, as shown in Figure 5. As a result, the process as disclosed in the
present disclosure, in which there is reduced exposure of cyclosporine to, for example,
KOLLIPHOR RH 40 at 55°C, can minimize this precipitation phenomenon which may be
due to a possible conversion of the cyclosporine to the less soluble CsA form. Thus, the
present disclosure provides for, among other things, improved storage stability.
20
EXAMPLE 5
Preparation method of the nanomicellar solution of Table 1
The polyoxyl 40 hydrogenated castor oil (Kolliphor RH40) was heated to about 50-60°C,
until it liquefies, prior to introduction into the 10L glass vessel. The cyclosporine (CsA)
25 was added while maintaining the vessel temperature at 55±2°C and dissolved by stirring at
approximately 200-300 RPM for 75 minutes and visually inspected to ensure it is a clear
solution with no visible particles. The temperature was gradually lowered to 35°C. Once it
is completely dissolved, the temperature was increased to 55±2°C. The octoxynol-40 is
then added. If the octoxynol-40 has solidified, it was heated at about 50-60°C until it
30 liquefies prior to its addition.
A portion (approximately 90%) of the Water for Injection (WFI) was charged into the
stainless-steel mixing tank and the temperature is maintained at 20-30°C throughout the
49
process. While stirring, the API mixture was added at 55±2°C to the mixing tank and
stirred for approximately 15 minutes while the remaining excipients were added in order
of sodium phosphate monobasic, then sodium phosphate dibasic, then sodium chloride,
and then polyvinylpyrrolidone.
After mixing for 15 minutes, the pH was checked and adjusted, 5 if necessary, to 6.8± 0.2
using hydrochloric acid (1N) or sodium hydroxide (1N). The solution was adjusted to the
final volume with WFI and filtered through 0.2 μm filter.
EXAMPLE 6
10 Preparation method of the nanomicellar solution of Table 1
The polyoxyl 40 hydrogenated castor oil (Kolliphor RH40) was heated to about 50-60°C,
until it liquefies, prior to introduction into the 10L glass vessel. The cyclosporine (CsA)
was added while maintaining the vessel temperature at 55±2°C for 20±2 minutes and then
stirred at approximately 200-300 RPM for 15 minutes. The temperature was reduced
15 gradually to 35°C under stirring and once it reaches the temperature 35°C, it is stirred for
60±5 minutes. The octoxynol-40 was then added. If the octoxynol-40 has solidified, it was
heated at about 50-60°C until it liquefies prior to its addition.
A portion (approximately 90%) of the Water for Injection (WFI) was charged into the
stainless-steel mixing tank and the temperature was maintained at 20-30°C throughout the
20 process. While stirring, the CsA mixture was added to the mixing tank at 35±2°C and
stirred for approximately 15 minutes while the remaining excipients were added in order
of sodium phosphate monobasic, then sodium phosphate dibasic, then sodium chloride,
and then polyvinylpyrrolidone.
After mixing for 15 minutes, the pH was checked and adjusted, if necessary, to 6.8± 0.2
25 using hydrochloric acid (1N) or sodium hydroxide (1N). The solution was adjusted to the
final volume with WFI and filtered through 0.2 μm filter.
EXAMPLE 7
Preparation method of the nanomicellar solution of Table 1 - process under high speed
50
The polyoxyl 40 hydrogenated castor oil (Kolliphor RH40) was heated to about
50-60°C, until it liquefies, prior to introduction into the 10L glass vessel. The cyclosporine
(CsA) was added while maintaining the vessel temperature at 55±2°C for 20±2 minutes
and stirred at approximately >450 RPM for 15 minutes. The temperature was reduced
gradually to 35°C under stirring and stirred for 60±5 minutes. 5 The octoxynol-40 was then
added. If the octoxynol-40 has solidified, it was heated at about 50-60°C until it liquefies
prior to its addition.
A portion (approximately 90%) of the Water for Injection (WFI) was charged into the
stainless-steel mixing tank and the temperature was maintained at 20-30°C throughout the
10 process. While stirring, the CsA mixture was added to the mixing tank at 35±2°C and
stirred for approximately 15 minutes while the remaining excipients were added in order
of sodium phosphate monobasic, then sodium phosphate dibasic, then sodium chloride,
and then polyvinylpyrrolidone.
After mixing for 15 minutes, the pH was checked and adjusted, if necessary, to 6.8± 0.2
15 using hydrochloric acid (1N) or sodium hydroxide (1N). The solution was adjusted to the
final volume with WFI and filtered through 0.2 μm filter.
EXAMPLE 8
Preparation method of the nanomicellar solution of Table 1 - process at higher temperature
20 The polyoxyl 40 hydrogenated castor oil (Kolliphor RH40) is heated to about 50-60°C,
until it liquefies, prior to introduction into the 10L glass vessel. The temperature was
increased to 127-130°C. The cyclosporine (CsA) was added while maintaining the vessel
temperature at 127-130°C and stirred at approximately 200-300 RPM for complete
dissolution. The octoxynol-40 was then added. If the octoxynol-40 has solidified, it was
25 heated at about 50-60°C until it liquefies prior to its addition.
A portion (approximately 90%) of the Water for Injection (WFI) was charged into the
stainless-steel mixing tank and the temperature was maintained at 20-30°C throughout the
process. While stirring, the CsA mixture was added at 127-130°C to the mixing tank and
stirred for approximately 15 minutes while the remaining excipients are added in order of
30 sodium phosphate monobasic, then sodium phosphate dibasic, then sodium chloride, and
then polyvinylpyrrolidone.
51
After mixing for 15 minutes, the pH was checked and adjusted, if necessary, to 6.8± 0.2
using hydrochloric acid (1N) or sodium hydroxide (1N). The solution was adjusted to the
final volume with WFI and filtered through 0.2 μm filter.
5 EXAMPLE 9
Stability Studies
Nanomicellar ophthalmic formulation of Example 6 was tested after being stored at
25oC/40%RH for 6 months.
The formulation was tested for change in appearance, pH, osmolality, viscosity,
10 Cyclosporine assay by HPLC method II, micelle size determination by Laser light
scattering method and particulate matter presence.
Tests Specifications Initial 3M 6M
Appearance Clear colorless solution,
essentially free from visible
particulate matter
Complies Complies Complies
pH 6.5-7.2 6.8 6.8 6.8
Osmolality 160-190mOsmol/Kg 169 166 175
Viscosity 1.3 -2.0 cP 1.4 1.4 1.4
HPLC method II
Cyclosporine assay 95.0 -105.0% of label claim 97.8 99.2 98.2
Total impurities ≤2.0% area 0.59 0.76 0.83
Micelle size
determination
Zavg: 13-16nm 15 14 14
PdI ≤0.2 0.13 0.15 0.10
Particulate matter
(USP 788)
The average number of
particles present in the units
does not exceed:
Stage 1 : by method 1 – Light
obscuration
6000 per contained ≥10μm NA NA NA
600 per container ≥25μm NA NA NA
Stage 2: method 2- Membrane
microscopic
6000 per contained ≥10μm NA NA NA
600 per container ≥25μm NA NA NA
Sterility No evidence of microbial
growth
Sterile NA NA
52
As observed from the above data, the formulation is found to be both chemically and
physically stable.
Unless indicated otherwise, the documents mentioned herein are incorporated by reference
in their entirety.
Even though certain specific embodiments are thoroughly described 5 in the present
application, it should be understood that the same concepts disclosed with respect to those
specific embodiments are also applicable to other embodiments. Furthermore, individual
elements of the formulations and methods disclosed herein are described with reference to
particular embodiments only for the sake of convenience. It should be understood that
10 individual elements of the formulations and methods disclosed herein are applicable to
embodiments other than the specific embodiments in which they are described.
In addition, it should be understood that the scope of the present disclosure is not limited
to the above-described embodiments, and those skilled in the art will appreciate that
various modifications and alterations are possible without departing from the scope of the
15 present disclosure. For example, the batch sizes may be altered by a person having
ordinary skill in the art while staying within the present disclosure.
53
WE CLAIM:
1. A method of making a stable nanomicellar ophthalmic formulation comprising:
0.09 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40,
about 0.20-0.550 wt % sodium phosphate monobasic,
about 0.23-0.465 wt % sodium phosphate dibasic,
about 0.05 wt % sodium chloride,
about 0.3 wt % povidone,
sodium hydroxide/hydrochloric acid to adjust the pH, and
water for injection,
wherein the method comprises the steps of:
a) mixing the cyclosporine with the hydrogenated 40 polyoxyl castor oil at a
temperature of 55°C±2°C or above to form a mixture A;
b) lowering the temperature of mixture A to a temperature of 35°C±2°C prior
to the complete dissolution of the cyclosporine, adding octoxynol-40 to form an
API mixture;
c) adding API mixture to Water for Injection (WFI);
d) adding remaining excipients to step (c) in the order of sodium phosphate
monobasic, then sodium phosphate dibasic, then sodium chloride, and then
polyvinylpyrrolidone; and,
e) adjusting the pH to 6.5 to 7.2 and bringing to the final volume with WFI.
2. The method of claim 1, wherein, mixing cyclosporine in step (a) at 200-300 RPM.
3. The method of claim 1, wherein, lowering the temperature of the mixture to
35°C±2°C in 40-50 minutes.
4. The method of claim 1, wherein stirring the mixture for 60±5 minutes at a
temperature of 35°C±2°C.
54
5. A stable nanomicellar ophthalmic formulation prepared by the method as described
in any of the preceeding claims.
6. The stable nanomicellar ophthalmic formulation of claim 5, wherein the osmolality
of the formulation is between about 150 to about 200 mOsmol/kg.
7. The stable nanomicellar ophthalmic formulation of claim 5, wherein the
formulation comprises cyclosporine form with characteristic XRD peaks at 2-theta (deg.)
6.9, 7.8, 9.4 and 15.9.
8. The stable nanomicellar ophthalmic formulation of claim 5, wherein the
formulation comprises an amorphous form of cyclosporine.
9. The stable nanomicellar ophthalmic formulation of claim 5, wherein the
formulation is substantially free of a cyclosporine form with characteristic XRD peaks at
2-theta (deg.) 7.4, 8.7, 14.4 and 17.5.
10. The stable nanomicellar ophthalmic formulation of claim 5, wherein the
formulation is substantially free of a cyclosporine form with characteristic XRD peaks at
2-theta (deg.) 8.5, 9.3, 11.6 and 20.3.